Back HCV Treatment Experimental HCV Drugs

Experimental HCV Drugs

AASLD 2015: MiR-122 Inhibitor RG-101 Suppresses Hepatitis C Virus with Single Dose

A single injection of RG-101, an experimental drug that targets the micro RNA miR-122 in liver cells, reduced hepatitis C virus (HCV) levels by more than 4 log in people with HCV genotypes 1, 3, and 4, and 21% of treated patients still had undetectable virus levels 28 weeks after dosing, according to research presented at the AASLD Liver Meeting in November.

alt

Read more:

FDA Approves Zepatier (Grazoprevir/Elbasvir) for Hepatitis C Genotypes 1 and 4

The U.S. Food and Drug Administration (FDA) this week announced its approval of Merck's Zepatier -- a once-daily coformulation containing the hepatitis C virus (HCV) protease inhibitor grazoprevir and NS5A inhibitor elbasvir -- for the treatment of HCV genotypes 1 and 4. In several Phase 3 studies grazoprevir/elbasvir taken for 12 weeks demonstrated cure rates exceeding 90% for various groups including people with liver cirrhosis, HIV/HCV coinfected patients, and people who inject drugs.

alt

Read more:

AASLD 2015: 3-Drug Combos for 8 Weeks Demonstrate High Hepatitis C Cure Rate

An interferon-free regimen containing Merck's grazoprevir, the NS5A inhibitors elbasvir or MK8404, and the experimental nucleotide polymerase inhibitor MK-3682, taken for 8 weeks, cured more than 90% of non-cirrhotic hepatitis C patients with HCV genotypes 1, 2, or 3, according to late-breaking research presented at the AASLD Liver Meeting in November.

alt

Read more:

AbbVie Opens Global Phase 3 Studies of ABT-493/ABT-530 Hepatitis C Regimen

AbbVie has started enrollment of a projected 1600 participants in 6 new international Phase 3 clinical trials evaluating a once-daily regimen of its investigational NS3/4A protease inhibitor ABT-493 and NS5A inhibitor ABT-530 for people with hepatitis C virus (HCV) genotypes 1 through 6, the company recently announced.

alt

Read more:

AASLD 2015: Grazoprevir/ Elbasvir Cures More than 90% of People with HIV/HCV Coinfection

Merck's grazoprevir/elbasvir combination cured 93% of people with HIV and hepatitis C coinfection, was well-tolerated, and did not appear to interact with antiretrovirals, according to final results from the C-EDGE Co-infection study presented at the 2015 AASLD Liver Meeting last month in San Francisco. These results confirm that HIV/HCV coinfected people respond as well to interferon-free therapy as those with HCV alone.

alt

Read more: